I read with great interest Elias and colleagues' recent metaanalysis in which 2-year follow-up data were used for all trials with the exception of ABSORB II [1] . However, sensitivity analysis using 2-year follow-up data from AB-SORB II does not change their summary result for target lesion failure (TLF) (RR 1.31; 95% CI 1.08-1.58; p = 0.004). Thus, based on this meta-analysis, we can conclude that bioresorbable vascular scaffolds (BVSs) are associated with worse safety and efficacy outcomes up to 2 years after implantation; however, it is not clear if this is true beyond 2 years.
